Effect of luteolin on the levels of glycoproteins during azoxymethane-induced colon carcinogenesis in mice.
Luteolin (LUT), a bioflavonoid has been used as a chemopreventive agent world-wide against chemically induced cancer. Hence we designed an experiment to assess chemopreventive action of LUT on lipid peroxidation (LPO) and glycoconjugates in azoxymethane (AOM)-induced colon carcinogenesis. Colon cancer was induced by 15 mg/body kg. body weight of AOM and administration of LUT (at the dose of 1.2 mg/kg. body weight) was till end of the study. Analysis of lipid peroxidative end products such as protein carbonyl (PC), malonadehyde (MDA) and conjucated dienes (CD) demonstrated significant increase in in AOM-induced animals with reduction by LUT (p<0.05) . Increased levels of glycoconjugates such as hexose, hexosamine, sialic acid, fucose and mucoprotein were analyzed in serum and colon tissues examined histopathologically by periodic acid Schiff's (PAS) staining were also reversed by LUT l(p<0.05) . The secondary marker of colon cancer mucin depleted foci (MDF) was assessed in control and experimental group of animals. A characteristic increase of MDF was observed in AOM- induced colon cancer animals. Treatment with LUT decreased the incidence of MDF. These results suggest that LUT alters the expression of glycoconjugates and suppress colon cancer. Hence, we speculate that LUT can be used as a chemopreventive agent to treat colon cancer.
Department of Biochemistry, University of Madras, Guindy campus, Chennai, India.
Ashok Kumar
AK
Pandurangan
Prakash
P
Dharmalingam
Suresh Kumar
SK
Ananda Sadagopan
Sudhandiran
S
Ganapasam
D058739:Aberrant Crypt Foci / Q000378:metabolism* / Q000473:pathology; D000704:Analysis of Variance; D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D001397:Azoxymethane; D003106:Colon / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D003110:Colonic Neoplasms / Q000097:blood / Q000139:chemically induced / Q000378:metabolism*; D005643:Fucose / Q000378:metabolism; D006001:Glycoconjugates / Q000097:blood / Q000378:metabolism*; D006023:Glycoproteins / Q000097:blood / Q000378:metabolism*; D006595:Hexosamines / Q000378:metabolism; D006601:Hexoses / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects*; D047311:Luteolin / Q000494:pharmacology*; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D009077:Mucins / Q000187:drug effects / Q000378:metabolism; D009088:Mucoproteins / Q000378:metabolism; D019158:N-Acetylneuraminic Acid / Q000378:metabolism; D050050:Protein Carbonylation / Q000187:drug effects
D016588:Anticarcinogenic Agents; D006001:Glycoconjugates; D006023:Glycoproteins; D006595:Hexosamines; D006601:Hexoses; D009077:Mucins; D009088:Mucoproteins; D005643:Fucose; D008315:Malondialdehyde; D019158:N-Acetylneuraminic Acid; D047311:Luteolin; D001397:Azoxymethane